

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/09790 A1**

- (51) International Patent Classification<sup>7</sup>: **A61L 31/04**, C08L 89/06
- (21) International Application Number: **PCT/EP01/08872**
- (22) International Filing Date: **1 August 2001 (01.08.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**MI00A001794** **2 August 2000 (02.08.2000)** **IT**
- (71) Applicants (*for all designated States except US*): **MEDI-OLANUM FARMACEUTICI S.P.A.** [IT/IT]; Via S. G. Cottolengo, 15, I-20143 Milan (IT). **OPOCRIN S.P.A.** [IT/IT]; Via Pacinotti, 16, I-41040 Corlo (IT).
- (72) Inventor; and
- (75) Inventor/Applicant (*for US only*): **PARMA, Bruna** [IT/IT]; Opocrin S.p.A., Via Pacinotti, 3, I-41040 Corlo (IT).
- (74) Agent: **GERVASI, Gemma; Notarbatolo & Gervasi,** Corso di Porta Vittoria, 9, I-20122 Milan (IT).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *with international search report*  
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/09790 A1

(54) Title: **COLLAGEN MEMBRANE ARRANGED AT MACROMOLECULAR LEVEL**

(57) Abstract: The present invention concerns double sided collagen membranes, one of which is porous, suitable for the adhesion and/or growth of cells, and a smooth one characterized in that the collagen fibres are arranged at macromolecular level. Moreover, the process for the preparation of such membranes is described and their use as supports for the adhesion and/or growth of mammalian cells in vitro and as matrices for tissue reconstruction.

## COLLAGEN MEMBRANE ARRANGED AT MACROMOLECULAR LEVEL

## FIELD OF THE INVENTION

The technical field of the present invention concerns the preparation of biocompatible supports particularly consisting of collagen membranes for tissue reconstruction.

## PREVIOUS ART

Collagen is a scleroprotein present in different ways in animal tissues and organs. In humans it is one of the most represented structural proteins and constitutes approx. 30% of the total proteins.

Various collagen types exist which differ mainly with respect to the function of the tissue or organ of origin. Ample literature is available for all collagen types relating to primary, secondary structure, composition, purity, uses (Marcel E. Nimni *Collagen Biochemistry, Biochemistry and Biomechanics, Biotechnology*, CRC Press Inc. Boca Raton Florida 1988; Cunningham and Frederiksen *Methods in Enzymology*, Academic Press, New York, 1-554,1982).

It is known that the properties of collagen do not depend solely on the structure of proteic monomers making up the triple helix of the fibre, but, above all, on the complex macromolecular organization that distinguishes this and other structural proteins with mechanical functions (e.g. myosin and tropomyosin in muscular fibres, etc.) and that envisages organization in fibrillae, their supercoiling, their organization in head-tail monomers and so on.

The macromolecular organization of the native collagen structures, is partly lost with the collagen extraction processes. It can be partly restored artificially, for instance by chemical cross-linking. This treatment restores, even if only partially, the mechanical resistance of the collagen fibrillae and makes the end product also more resistant to proteolytic digestion.

So far many collagen based preparations have been introduced into medical practice alone or with other natural components, both in gel form and feltwork, membranes or plasters, as stimulating agents for the cicatrization of wounds, or as vehicles or devices for the slow release of other drugs or as matrices suitable for interaction with cells.

The importance of collagen as a substrate suited to favouring interaction and cellular growth is in fact known. Also known is the preference of cellular lines of different origin for the various collagen types: for instance skin fibroblasts and endothelial epithelial cells (Murray J.C. et al. Cancer Res. 40,347, 1980; Wicha  
5 M.S. et al. Exp. Cell Res. 124,81, 1979) grow better on type IV collagen (a collagen type present in the basal membrane) while chondrocytes prefer the type II collagen (present in the hyaline cartilage) (Hewit A.T. et al. Proc. Natl. Acad. Sci. USA 77,385, 1980) but they also adapt to grow on collagen I and III.

In this type of application the presence of fibronectin, endogenously produced by  
10 the cells (Grinnel F. et al. Proc. Natl. Acad. Sci. USA 75,4408 (1978), also proved important for the adhesion of fibroblasts on the collagen substrate (Pearlstein E., Int. J. Cancer 22,32, 1978) and that of chondronectin for the interaction of chondrocytes with the collagen (Hewit et al. Proc. Natl. Acad. Sci. USA 77,385, 1980).

15 In the literature a number of collagen applications and extraction and preparation methods are available.

The US patent 5,785,983 claims a preparation process of type I collagen membranes, chemically unmodified, obtained from collagen gel distributed in non-stick Teflon trays, by slow exsiccation under suitable conditions of temperature,  
20 vacuum and nitrogen flows. The membranes thus obtained are proposed in the cicatrization of wounds and burns and as interposition barriers to prevent adherences after internal surgery operations. The preparation of collagen gel from bovine tendon is described in WO98/ 44809.

Many patents, such as EP 284789, exist on feltwork or collagen membranes  
25 obtained by freezing and rapid lyophilization of collagen solutions in gel form. The structure of such feltwork is not organized since such processes fix, as in an instant photograph, the disorder of the collagen fibres in solution. As said in EP 284789, the structure obtained is not suitable to allow cell growth. In the literature is described how the pore size of such feltwork is regulated by controlling the  
30 temperature of freezing, However, the resulting pores have a diameter exceeding that of cultured cell, which are allowed to pass through it (Boyce et al. J. Biochem. Mat. Research, 1988 22:939-957). Moreover, these membranes are of limited

resistance since the collagen, denatured in the extraction process, is not sufficiently reorganized.

The patent WO95/18638 claims reabsorbable collagen membranes, as a guide in the repair of tissues and characterized by two opposite sides, a fibrous one  
5 suitable for the growth of cells and a smooth one to inhibit adherences. Such membranes are obtained from peritoneal or placental membranes from various mammals, among which calves, and are prepared by a rough process of cleaning, dehydration and degreasing with acetone and N-hexane. Due to the preparation method used, the membranes have the shape and the dimensions of the organ  
10 from which they originate and also the distinctive characteristics, namely porosity and the collagen type of which they are made up, closely reflect those of the starting tissue.

The patent WO 96/25961 claims reabsorbable matrices of type II collagen (from cartilage) suitable for natural cartilaginous tissue reconstructions. Such matrices  
15 are prepared by freezing and/or lyophilization and can be combined with glycosaminoglycans

The patent WO99/19005 claims a multilayer membrane including a matrix mainly of collagen II consisting of a spongy side and a relatively impermeable side. This membrane is prepared by successive stratifications of collagen matrices  
20 (previously degreased with acetone), and portions of collagen gel are then lyophilized on such membranes in successive and alternate cycles.

So far, the preparation processes of the collagen membranes envisage the extraction of collagen in semi-purified solid or gel form that is quickly frozen and dried. Generally, the collagen is subsequently chemically modified by cross-  
25 linking, occurring in a random way without macromolecular reorganization typical of the native fibrilla, to increase the mechanical resistance of the membrane. Alternatively, the membranes can be prepared by slow evaporation of a collagen gel, or directly prepared from collagen membranes pre-existing in nature and only partially purified.

30 One unsolved technical problem which still remains is to produce collagen membranes in which the collagen is arranged at macromolecular level in a more similar way to its natural form, which are endowed with mechanical resistance and

elasticity, though being mouldable, according to the requirements of the reconstruction site.

#### SUMMARY

The present invention concerns double sided collagen membranes with a porous side suitable for the adhesion and/or growth of cells and a smooth side, characterized in that the collagen on the smooth side is arranged at a macromolecular level in a similar way to the native one. The collagen comprising such membranes is of type I, II, III or IV. An additional subject of the present invention is a process for the preparation of collagen membranes characterized in that a collagen gel is strained and desiccated very slowly on plates or trays on which an electrostatic charge has been induced, and the use of the collagen membranes as supports for the adhesion and/or growth in vitro and in vivo of mammalian cells, particularly in the applications of tissue reconstruction (for instance of epithelial, bone, cartilaginous or connective tissue) matrix-guided or induced.

#### DESCRIPTION OF THE FIGURES

**Figure 1. Smooth side of the membranes as seen under the Scanning Electron Microscope (SEM).**

The sample was treated as follows: 2 small portions of the membrane produced according to the invention (approx. 5 x 3 mm) were cut out from each sample. These were placed on a special metallic support (stub) exposing the smooth side for each sample (A, B and E). The samples were covered with a palladium gold film to render its surface conductive and allows its observation under the SEM.

SEM analysis of the shiny surface of the samples highlighted the presence of fibres arranged at macromolecular level in the smooth part.

**Figure 2. Porous side of the membranes as seen under the Scanning Electron Microscope (SEM).**

The sample was treated as follows: 2 small portions of the membrane produced according to the invention (approx. 5 x 3 mm) were cut out from each sample. These were put on a special metallic support (stub) exposing the opaque part (marked with a light incision on the support) for each sample (A, B and E). The samples were covered with a palladium gold film to render its surface conductive

and allow its observation under the SEM.

SEM analysis of the opaque surface of the samples highlighted the presence of superficial irregularities, protuberances and "bubbles" which confer a certain porosity to the membrane.

5 **Figure 3. Resistance of the membranes to digestion with collagenase.**

Membranes produced according to the present invention (batch P323 and P50027) and commercially available membranes (ChondroGide, Antema F and Antema S) were subjected to enzymatic digestion with collagenase. The content of free hydroxyproline, an indication of enzymatic digestion, was measured in the  
10 samples after 24 hours: the membranes according to the present invention proved more resistant after such period.

**Figure 4. Mechanical resistance curve of the membranes according to the present invention.**

Small dog bone shaped samples (maximum length 76.7 mm and the thinnest part  
15 4 mm wide and 22 mm long) were cut from the membranes produced and subjected to tensile tests, according to conventional processes, with Chantillon apparatus HTC mod. (USA). The mean resistance values measured in Kg of ultimate tensile strength for 3 families of samples (3-6 samples for each family) of different thickness, were displayed in graph form. The relationship between mean  
20 thickness (x), in mm and mean load at break ultimate tensile strength (y) of the membranes is described by the logarithmic equation:  $y = 11.42 + 7.08 \log x$ , with a correlation index  $R^2 = 0.999$ .

**Figura 5. Optic microscopy of the collagen membranes prepared according to Example 7.**

25 Semi-fine sections, perpendicular to the membrane surface, of the 40046 membrane were stained with basic dyes of the thiazine group and observed under the optic microscope. One surface (the upper one in the figure, corresponding to the side in contact with the electrostatically charged side of the tray during the dry phase) is smooth, compact and intensely coloured. Approaching toward the  
30 opposite surface, which corresponds to the lower surface in the picture (which is the one exposed to the air during the drying phase) the structure becomes is less homogeneous, more loose and uneven. Enlargment 50X.

**Figure 6. Collagen membranes batch 40046, seen at the electron microscope.** Semi-fine sections of the collagen membranes prepared according to example 7, perpendicular to the membrane surface, were prepared according to Maunsbach AB and Afzelius B. 1999, Academic Press. It can be observed that the lower part of the picture, corresponding to the side in contact with the air during the dry phase (opaque side) is irregular, while the opposite side in contact with the electrostatically "charged tray" (corresponding to the upper part of the figure, is more regular and the collagen fibres are more compact and arranged in the longitudinal direction

**Figure 7. Growth of dermal fibroblasts on collagen membranes 40046 compared growth in cell-culture treated plastic wells.** The growth of dermal fibroblast on collagen membrane prepared according to example 7 (40046) was compared to the growth on cell-culture treated plastic wells, as measured by the MTT test, as described in example 13. Fibroblast on collagen membrane (-○-) and fibroblast on plastic wells (-●-). O.D. optical density.

**Figure 8. Dermal fibroblasts after 6 days of growth on collagen membranes observed by confocal microscope.** Dermal fibroblasts were plated on collagen membranes prepared according to the invention and after 6 days were stained as described in example 14. Cells were allowed to reach confluency. Microscopy observation showed that cells grew at different levels in the membrane. At day 6, the fibroblasts, of polygonal shape and elongated, were at confluence as they covered all the membrane space (labeling with Phalloidine) Obj: 10.0 Zoom:1.430.

**Figure 9. Histomorphometry of collagen membranes according to the invention and commercial collagen membranes.** Human chondrocytes (1x10<sup>4</sup>) were allowed to grow for 7 days on collagen membranes produced according to the invention (40046, 40036 and 40049A/S) or according to the invention but lyophilized (40046LL), or on commercially available membranes (P322 and C-G). At the end of the 7 days period, the membranes, which were colonized by cells at a different extent were stained with Safranin-O, which is specific for the extracellular matrix sulphate groups, as described in example 16. Since only vital condrocytes synthetize cartilageneous matrix, a positive safranin staining indicates that the cells are alive and didn't loose their ability. The histomorphometry data



were obtained by plotting for each membrane the percent of the entire surface which was colonized by chondrocytes after a 7 days period (Aa %).

**Figure 10. Microscope analysis of a commercially available collagen membrane (ChondroGide).** Chondrocytes grown on a commercially available membrane were stained with safranin-O. Cells are few, elongated and not intensely coloured with the dye, indicating a low ability to synthesize the extracellular matrix. They are arranged in a single layer on the membrane.

**Figure 11. Microscope analysis of the 40046 membrane produced according to example 7.** a) Chondrocyte grown on membrane 40046 were stained with safranin-O. Chondrocytes grown on 40046 membrane are morphologically very different from the ones showed in figure 10: they are rounded, intensely coloured because of the presence of abundant sulphate groups and they grow in multilayer, showing the ability to penetrate into the membrane. b) Enlargement of a particular.

#### DETAILED DESCRIPTION OF THE INVENTION

Object of the present invention are double sided collagen membranes, with a smooth side and a porous one, the former organized at the macromolecular level and the latter suitable for the growth of mammalian cells. Such membranes are characterized in that the collagen is arranged at macromolecular level on the smooth side and the fibrillae are organized in the bidimensional space. The membranes of the present invention are endowed with a high mechanical resistance and are also slowly reabsorbable, therefore proving useful in applications of *in vivo* tissue reconstruction. One additional aspect of the invention in fact concerns the use of collagen membranes for tissue reconstruction: these are in fact biocompatible and are colonized *in vitro* by mammalian cells preferably chosen from: staminal cells, fibroblasts, epithelial cells, endothelial cells, osteocytes, chondrocytes.

The membranes of the present invention mainly consist of collagen of type I, II, III, or IV, or mixtures of at least two of the different collagen types. They have a collagen content of between 70% and 95%, measured as dry collagen residue and corresponding to a total hydroxyproline content of between 9% and 13% and a water content not exceeding 15%. They can comprise other constituents, be for instance natural substances and biological components of specific body districts

"areas" or characteristics of particular organs or particular functions, such as, for instance, hyaluronic acid or glycosaminoglycans in various percentages.

The membranes of the present invention are not immunogenic, since the telopeptides that constitute the terminal part of the collagen fibrilla are removed by enzymatic digestion with protease: the collagen constituting such membranes is therefore also called as atelocollagen (collagen without the terminal telopeptides). An additional embodiment of the present invention is the process for the preparation of such collagen membranes, characterized in that a collagen gel is poured into electrostatically charged trays or plates and subsequently slowly dried, for a time exceeding 40 hours, or until obtaining membranes with a water content not exceeding 15%. Exsiccation of the collagen gel preferably takes place at a temperature of between 10 and 40°C, preferably between 20 and 30°C, still more preferably at 26°C, in a turbulence free ventilated incubator, namely an incubator with diaphragmed air flow intake.

After exsiccation, the membranes were sterilized by physical treatment, for instance radiation with  $\gamma$  rays at a dose of between 2.5 and 25KGy.

The trays or plates are electrostatically charged according to method known in the art i.e. by rubbing them with suitable materials for example, or preferably by placing the trays between the plates of a condenser. The induction of an electrostatic charge on the trays can be checked by an Ionizing Fan (RPO Electronic snc, Milan) working at 220 primary volt, secondary volt 6000 VA power 50 Hz 50/60. The trays are of standard shape or of suitable shape and size to give the membrane a shape fit for the subsequent use.

Alternatively, the collagen gel can be poured on trays subjected to an electric field set in a suitable way, maintained if necessary also during the exsiccation step of the gel.

The induction of an electric field or an electrostatic charge allows, surprisingly, and unlike the known art, the macromolecular reorganization and orientation of the collagen into fibrillar structures similar to those of the native tissue, which allow the attainment of membranes endowed with maximum resistance and tenacity.

The gel used in the process, according to the invention, consists essentially of collagen at a concentration of between 0.5 and 6% (weight/volume, where the

weight is denoted as dry collagen residue), preferably at a concentration of between 1% and 4%, still more preferably between 2% and 3%. Various natural and non-natural substances can be optionally added to the gel, or biological components of specific district of the organism or of particular tissues. An example  
5 of biological components which can be added are animal or vegetable polysaccharides or matrix proteins namely fibronectin; laminin, etc.

In one of its preferred embodiments, the process for the preparation of collagen gel essentially comprises the following steps:

- a) mechanical mincing of a connective tissue and homogenization in a collagen  
10 suspension,
- b) treatment of the collagen suspension with proteolytic enzymes in aqueous solution at acidic pH, optionally followed by filtering,
- c) alkaline treatment of the suspension until a pH higher than 8 and its neutralization with acids up to a pH preferably comprised between 5 and 6,
- 15 d) precipitation of the collagen fibers by addition of an acid solution (salting)
- e) resuspension of the collagen precipitate at a concentration comprised between 0.5 and 6% (weight/volume) of dry collagen residue, in a slightly acidic solution such as an aqueous solution containing a weak acid, and up to obtain a collagen gel in acidic solution. According to a particularly preferred embodiment, two  
20 additional steps are added in between step d) and e), which are respectively the steps d') of: resuspension of the precipitate in a strong alkaline solution with mixing for a time of at least 30', and of d'') precipitation of the collagen fibers by salting of the alkaline solution (slowly adding an acidic solution) to pH values comprised between 5 and 6. These two additional steps, which comprises a  
25 second precipitation of the collagen fibres, allow for a better purity of the collagen gel and, consequently, of the membranes produced by this gel. The membranes according to these additional steps showed also to be more elastic.

According to the process of the present invention the starting connective tissue is preferably obtained from mammals. A cartilaginous tissue is used, such as that of  
30 the trachea, in the case in which one wishes to obtain membranes mainly consisting of type II collagen, or a connective tissue is used that contains mainly type I collagen, namely tendon, preferably derived from equine, bovine, swine

animals, or connective tissue derived from the basal lamina, that mainly contains type IV collagen. The final type of use of the membrane determines the most appropriate choice of starting tissue according to what is known in the art and also in consideration of the amounts required. Other sources of collagen can be used  
5 as an alternative to mammalian connective tissue, for instance cartilaginous or osteo-cartilaginous tissue of fish.

The mincing of the starting connective tissue (step (a) of the process) is obtained by treatment of the tissue, to which water or an aqueous solution is added, preferably in an amount equal to 6-30 volumes of the initial tissue volume, with a  
10 rotating blade mixer until a collagen suspension is obtained. The collagen suspension contains collagen particles preferably less than 25-30 mesh in size. Other systems of mincing or homogenization are known to the person skilled in the art and can therefore be used as alternatives to present step a). A further reduction of the collagen particles, after homogenization, is preferred and is  
15 carried out by treating the collagen suspension with a micronizer, for instance the Waring Blender at 15-20,000 revs./min pulses.

The suspension thus obtained is acidified and treated (step b of the process) with proteolytic enzymes, of non-collagenasic kind, preferably with pepsin, at acidic pH, comprised between 2 and 3, preferably 2.5. Methods for proteolytic digestion and  
20 enzyme:collagen ratio are known in the art and may be adjusted accordingly. The proteolytic treatment has the double effect of degrading possible contaminating proteins and of removing the telopeptides of the collagen, which are strongly immunogenic. The collagen obtained is atelocollagen, since it is locks the terminal immunogenic telopeptides. Treatment with pepsin is preferably performed for a  
25 period of time comprised between 10 and 20 hours, still more preferably 16 hours and is accompanied with agitation for the first 2-4 hours.

Optionally the collagen suspension can be filtered, through sieves, with a porosity preferably comprised between 20 and 100 mesh, preferably at 25 mesh.

The suspension is subsequently treated with alkali according to step (c) preferably  
30 with a concentrated solution of a strong base, preferably NaOH, up to a pH exceeding 8, preferably more than 10. This is achieved by alkaline treatment which has the double effect of removing possible contaminating agents and,

partially, the glycosidic residues.

The pH of the collagen suspension is therefore neutralized with a solution of a strong acid, up to a pH of between 5 and 6, preferably a pH of approx. 5.5. The alkalization and the successive neutralization, (step (c) of the process), are preferably very gradual to avoid a massive precipitation of the collagen fibres.

Alternatively, as in the case in which strong alkalization of the material is unnecessary, or in other cases known to the person skilled in the art, the pH can be brought to values comprised between 5 and 6, directly after the enzymatic digestion at acid pH with a strong base.

- At a pH of comprised 5 and 6 the collagen precipitates by salting as a whitish mass that can be collected and separated. According to a preferred embodiment, this whitish mass is resuspended in a strong alkaline solution, such as NaOH 1N and left under mixing for 1 hour. After that, collagen is precipitated by addition of an acid solution (salting) at pH values comprised between 5-6. A collagen gel is therefore obtained by resuspending the collagen precipitate at a concentration (denoted as a percentage in weight of the dry collagen residue) comprised between 0.3 and 6%, preferably between 0.5 and 4%, still more preferably 2%, preferably after removal of the precipitation salts by washing with sterile distilled water, in a solution diluted with a weak acid, preferably acetic acid at a concentration comprised between 0.1 and 1% (w/v), preferably 0.3%. As an alternative to acetic acid, other weak acids, for instance citric acid, ascorbic acid or tartaric acid, at a concentration comprised between 0.5 and 5%, can be used. This solution can be optionally further homogenized in order to help the resuspension of the precipitate. After resuspension, the collagen solution is preferably degassed.
- It is then poured very slowly into electrostatically charged trays or plates, as described above, of suitable shape and dimensions, in amounts corresponding to the desired membrane thickness, considering the loss in volume linked to exsiccation. The membranes thus obtained are then sterilized by physical methods for example, namely irradiation with  $\gamma$  rays at a dose of between 2.5 and 25 KGy.
- In one of its further embodiments of the invention concerns collagen membranes obtainable according to the processes described: namely the one which comprises the pouring of a collagen gel into electrostatically charged trays and the one which

comprise the preparation of such gel according to steps a)-e) and a)-e'') of the process, as previously described. Also comprised in the present invention is the collagen gel obtainable according to steps a)-e) and a)-e''). The collagen gel can be also mixed with natural substances and/or biological components of specific tissues or organic areas (e.g. glycosaminoglycans, hyaluronic acid etc.), before pouring into the electrostatically charged plates to obtain mixed composition membranes as close as possible to the specific natural composition of the tissue to be repaired.

In a further embodiment of the invention concerns the use of the collagen membranes according to the invention, as supports for the adhesion, colonization and/or growth of mammalian cells of various origin, e.g. staminal cells, fibroblasts, epithelial or endothelial cells, chondrocytes, osteocytes, both for *in vitro* systems, and *ex-vivo* systems, namely those where the cells of the patient are removed and put in culture *in vitro*, where they are amplified or simply made to adsorb or to adhere to the membrane. Therefore, in a further embodiment these membranes are for use in therapy. In particular they are used either colonized or not by autologous or heterologous cells, for the matrix guided tissue reconstruction, of tissues namely cartilaginous or osteo-cartilaginous tissue, epithelial or endothelial tissue or connective tissue. For the purposes of the present invention the terms matrix or support are used indifferently, simply defining both a physical framework that the cell uses to both adhere and/or grow also tridimensionally, as well as a substrate capable of interacting with the cellular mechanisms of adhesion, colonization or proliferation. In the case in which the collagen membranes, according to the present invention, are used as matrices or supports for the adhesion, colonization or growth of cells, the membrane becomes a cellular matrix, useful for the matrix guided tissue reconstruction purposes.

#### EXPERIMENTAL PART

##### **Example 1. Preparation of collagen gel from cartilage**

Cartilage containing mainly type II collagen, derived from bovine trachea was previously degreased mechanically, frozen at -20°C and broken up into fragments of approx. 2- 3 cm of diameter. 56 g of such fragments was placed in 900 ml of distilled water and ground in portions in blender model PBI 16 at 7400 rpm.

The white fibres obtained were put in 15 litres of demineralized water, brought to pH 2.51 with 30% HCl and added with 0.588 g of pepsin (700 FIP-U/g- 19917 Merck). The mass was kept under agitation for 2 hours and the pH was kept at 2.5 with HCl.

- 5 After a one night rest the fibres, separated by decantation, were homogenized in the blender at 6800 rpm, filtered through a sieve with dimensions  $\leq 25$  mesh and added to the mother-waters. A solution of 15% NaOH was added up to pH 5.5. The collagen precipitate was separated and washed with 2 volumes of water at pH 5.5. 107.1g of damp fibres were obtained to which 311.6 ml of distilled water and  
10 0.93 g of glacial acetic acid were added.

In these conditions the collagen absorbed water and assumed a jelly form. The gel was homogenized in blender model PBI 16 at 8400 rpm and was observed to have a dry residue of 4.51%. 310 ml of water were then added and 621 ml of gel were obtained by homogenization having a dry residue (DR) of 2.03 % and  
15 corresponding to a 2% collagen gel.

**Example 2. Preparation of collagen gel from horse tendon.**

- 50 g of horse tendon, corresponding to a dry residue of 35.5% were put in 900 ml of H<sub>2</sub>O for 4 h and manipulated to break the granules. They were then transferred into 15 L of H<sub>2</sub>O brought to pH 2.5 with HCl in which 1.5g of pepsin were dissolved  
20 (Merck 700 U. FIP/g) and enzymatic digestion was allowed to proceed for approx. 20 h at approx. 15°C.

The larger tendon fragments were eliminated by filtering on sieves of 25 mesh. The suspension was then brought to pH 5.4 with commercial NaOH and the collagen precipitate collected in approx. 2 h. The precipitate was collected by  
25 decantation and 7.5 L of water at pH 6 were added.

The fibres were washed by agitation, left to rest for 1h and again removed by decantation. Washings were repeated all 3 times. 43 g of damp fibres were obtained from which, by addition of 0.376g glacial acetic acid, 82 ml of water and homogenization, were obtained 125 g of collagen gel having 2.45% dry residue.

30 **Example 3. Large-scale preparation of collagen gel.**

500 g of horse tendon and 10 L of distilled water, were subjected to mashing by Rayneri turbotest SB endowed with sharp, curved blades rotating at 1500

revs./minute then with Rayneri turbotest H 002 then with INOX Waring blender micronizer at a speed of 15-20.000 rpm/min with pulses.

The suspension was left to rest until swelling (approx. 2- 4 h). The micronized tendon was transferred into a 200 L INOX reactor containing 140 L of distilled water, together with 5.88 g of Merck pepsin at 700 U FIP/mg and hydrochloric acid q.s. at pH 2.5. Agitation was maintained for 2- 4 h and the suspension was then kept at rest overnight at pH 2.5.

The reaction mass was filtered by sieving at 25 mesh and the filtrate brought very slowly to pH 5.5 with commercial sodium hydroxide 30%. The collagen fibres precipitated and were washed 3- 4 times with distilled water at pH 5.5 up to a chloride concentration of < 50 ppm.

The collected and weighed fibres were then dispersed in an aqueous solution of 0.3% acetic acid until a collagen concentration of 2% expressed as dry residue. 12.3kg of gel were obtained.

#### 15 **Example 4. Preparation of membranes from collagen gel.**

The gel obtained according to the previous examples was stratified in trays previously charged with electrostatic current and air dried at 26°C for 56 h. The electrostatic charge was checked by an Ionizing Fan (RPO Electronic snc, Milan) working at primary volt 220, secondary volt 6000 VA power 50 Hz 50/60.

20 Membranes named A, B, E, were obtained which were sterilized by  $\gamma$  rays (gamma) at 25 KGy. The membranes thus produced were subjected to morphological analysis, tests of degradability by collagenase, permeability to water vapour according to the standard ASTM-E 96-90, and tensile tests according to conventional processes.

25 The membranes A, B, E were shown to have 3, 6, 9 mg/cm<sup>2</sup> of dry residue.

#### **Morphological analysis**

An initial characteristic of the membranes thus obtained was also detectable to the naked eye: in fact, also to the naked eye the sheets showed two different surfaces, an opaque side and a shiny one. This different superficial morphology was better characterized by observation both with the stereomicroscope and the Scanning Electron Microscope (SEM).

30 The analysis was carried out on 2 x 2 cm side samples cut out from the original



sheets. The specimens were put as such under a stereomicroscope (Nikon, Japan).

For SEM analysis the sample was treated as follows: 2 small portions of material (approx. 5 mm x 3 mm) were cut out from each sample. These were placed on a special metallic support (stub) exposing for each sample (A, B and E) the shiny part and the opaque one (marked with a light incision on the support). The samples were covered with a palladium gold film to render its surface conductive and allows its observation under the SEM.

SEM analysis of the surfaces of the three samples highlighted the presence of fibres arranged at macromolecular level in the shiny part (see figure 1), while, in the opaque part, some superficial irregularities, protuberances and "bubbles" were visible giving a certain porosity to the membrane (see figure 2).

The thickness of the samples, measured with a digital micrometer, is shown in Table 1.

Table 1

Sample A <i>mm</i>	Sample B <i>mm</i>	Sample E <i>mm</i>
0.046	0.081	0.106
0.039	0.056	0.082
0.044	0.068	0.086
0.036	0.067	0.094
0.056	0.057	0.092
0.048	0.062	0.112
0.035	0.065	0.101
0.028	0.051	0.117
Mean Values: 0.041	0.063	0.099
$\sigma^*$ values 0.0087	0.0092	0.0124

\*  $\sigma$ : standard deviation

#### Degradability test in the presence of collagenase

The collagen membranes batched P323 and P 50027, prepared as described in the previous examples and commercially available collagen membranes, were

subjected to enzymatic degradation with bacterial collagenase (EC 3.4.24.3 from Clostridium Histolyticum I, 310 U/mg Sigma C-0130) 50 µg/ml, for 24 h in buffer at 37°C, for a comparative assay. Concentrations in µg/ml/24h of hydroxyproline hydrolyzed by collagenase were measured in the bath with a colorimetric method  
5 based on p-dimethylamminobenzoaldehyde.

Figure 3 shows that the samples P323 and P50027, obtained as described in the previous examples, are not degraded by the collagenase enzyme after 24 hours, while other commercial products namely Chondro-gide and Antema, are considerably degraded already after 24 hours, indicating that the membranes  
10 prepared according to the present invention are more resistant to degradation.

#### Permeability to water vapour

The tests were carried out on the samples (A, B, E) obtained as indicated in the previous examples, according to the so-called "water" test as described in the "Standard test method for water vapour transmission of materials," provided for by  
15 the standard ASTM E 96-90.

The WVT (water vapour transmission) values were obtained in the test according to the formula:

$$WVT = (G/t)/A$$

where:

20 A= area of the membrane;

G= variation in weight of the water in the measurement chamber, (grams)

t= time (hours),

and are shown together with the values of permeance, permeability and thickness of membranes in Table 2:

Table 2

Sample	G/t (g/h)	WVT (g·h <sup>-1</sup> ·m <sup>-2</sup> )	Permeance⊗ (g·Pa <sup>-1</sup> ·h <sup>-1</sup> ·m <sup>-2</sup> )	Permeability (g·Pa <sup>-1</sup> ·h <sup>-1</sup> ·m <sup>-1</sup> )	Thickness (mm)
A	0.201	66.6105	7.138*10 <sup>-3</sup>	0.7138*10 <sup>-11</sup>	0.01
B	0.200	66.2791	7.102*10 <sup>-3</sup>	2.9828*10 <sup>-11</sup>	0.042
E	0.205	69.9361	7.494*10 <sup>-3</sup>	4.4964*10 <sup>-11</sup>	0.062

The permeance was calculated using the following formula:

$$\otimes \text{ Permeance} = \text{WVT} / S (R_1 - R_2)$$

5 and for the conditions adopted:

$$S = 46.66 \times 10^2 \text{ Pa and } R_1 - R_2 = 0.5 \text{ (value expressed as a number fraction)}$$

The mean permeability was calculated from the permeance values using the following formula:

$$\text{Permeability} = \text{permeance} \times \text{membrane thickness}$$

10 From table 2 it is seen that the permeability is directly proportional to the thickness of the membranes and besides that the permeability values of membranes prepared as described in the previous examples, are between  $0.7138 \times 10^{-11}$  and  $4.4946 \times 10^{-11}$  (g·Pa<sup>-1</sup>·h<sup>-1</sup>·m<sup>-1</sup>) for membranes with a thickness of between 0.01 and 0.062 mm.

15 Tensile strenght tests

From the original membranes prepared according to the present process, "dog bone" (three different batches) shaped specimens were cut out, of maximum length 76.7 mm, the thinnest part 3-6 mm wide and 22 mm long. The tensile tests were carried out with Chantillon apparatus. mod HTC (USA), according to  
20 conventional processes.

The values shown in table 3 were obtained.

Table 3: tensile strenght test

Sample	Thickness mm	Load at break kg
A1	0.04	0.4
A2	0.03	0.4
A3	0.03	0.5
A4	0.03	0.25
A5	0.015	0.5
A6	0.02	-
<b>Mean</b>	<b>0.0275</b>	<b>0.341</b>
B1	0.07	3.1
B2	0.06	3.0
B3	0.07	3.1
B4	0.08	4.1
<b>Mean</b>	<b>0.07</b>	<b>3.325</b>
E1	0.11	5.0
E2	0.12	4.5
E3	0.12	4.5
<b>Mean</b>	<b>0.113</b>	<b>4.66</b>

It can be demonstrated that the membrane thickness is correlated to its load at break with a logarithmic relationship (see Figure 4) described by the following equation:

$$y = a \log(x) + b$$

In particular, for the mean values shown in the table, the value a is 7.08 and the value b is equal to 11.42 and the equation therefore becomes:

$$y = 7.08 x + 11.42, \text{ with } R^2 = 0.999$$

as measured for film thickness values comprised between 0.01 and 0.062 mm.

#### **Example 5: Preparation of membranes from collagen gel**

3 Kg of 2% collagen gel, prepared according to example 4, were diluted 1:2 with 0.3% acetic acid and shaken in a Rayneri mixer (endowed with sharp, curved blades, and rotating working at 1300 rpm) for 1.5 hours. They were then

transferred into a two-speed prototype planetary mixer, (dedicated), in the vacuum (76 cm Hg) and therein kept for 2.5 hours for degassing.

The gel was then poured into trays made of melaminic plastic material, of size 25.5 x 16.5 cm or other size, previously charged with electrostatic current, at the  
5 thickness of 1.3 cm gel or other thickness in relation to the resistance that one wishes to give to the membrane.

The trays were put in an incubator on strictly levelled shelves and subjected to low ventilation of sterile air for 96h. The incubator works with a controlled no. of changes/h, and was set to 26 °C.

10 The air flow intake was diaphragmed so as not to brush the trays of collagen gel in any way and the internal geometry of the incubator was such as to prevent the formation of air vortices.

The trays are previously electrostatically charged by rubbing. The actual presence of electrostatic charge was checked by an Ionizing Fan (RPO Electronic snc,  
15 Milan) working at primary volt 220, secondary volt 6000 VA power 50 Hz 50/60. The chemical-physical analysis of the batch of membranes prepared according to the process gave the following values:

Exsiccation loss	=	11.72% o.d.b. (on a dry bases)
Total hydroxyproline	=	12.39% o.d.b.
20 Total nitrogen	=	15.80% o.d.b.
Sodium	=	0.28% o.d.b.
Chlorides	=	0.19% o.d.b..
Sterility	=	sterile

**Example 6. Growth of fibroblasts on collagen membranes.**

25 The study was performed on human fibroblasts at the 2<sup>nd</sup>-3<sup>rd</sup> passage in culture. The cells were obtained from parodontal ligament.

At the beginning of experimentation the cells were elongated in parallel alignment as characteristic of fibroblast cells (sample OP) or in randomized alignment (sample B), or they were star-shaped in randomized alignment in sample A and C  
30 while replicative capacity was as in the control.

The following membrane batches were compared:

Sample A: membrane of type I collagen from bovine Achilles tendon, cross-linked

with formaldehyde (BIOMEND, Collatech);

Sample B: membrane of type I collagen and of Chondroitin-4-sulphate, extracted from bovine skin, cross-linked with diphenylphosphorylazide (PAROGUIDE, Celectica);

- 5 Sample C: sponge of type I collagen from bovine skin not cross-linked, (GINGISTAT, Colectica);

Sample OP: membrane of type I collagen from equine Achilles tendon, produced according to that described in example 5;

- Small 1x1cm squares of each membrane were placed in wells of NUNC plates together with 20000 cells per well in PBS (Dulbecco' Phosphate Buffered Saline). The suitable growth medium was then added to the wells and the cells were then incubated at 37°C; Platelet Growth Factor BB (PGF-BB) 50 ng/ml (Boehringer M.) was also added to the culture medium in some tests. The control consisted only of cells without membrane.

- 15 At the end of the experiment (72 hours) all the samples were trypsinized (incubation in 200 µl of 0.25% trypsin for 5') so as to detach the cells from the various substrates and make them available for counting. The samples were also observed under the optic microscope and SEM before trypsinization.

The following data was then collected:

- 20 1) Cell count: number of total cells present in the well at 72 hours:

Control of A	22000
Control+ PGF-BB	24750
Sample	0 (<5000)
Sample A+ PGF-BB	0 (<5000)
25 Control of B, C, OP	21000
Control+ PGF-BB	36000
Sample B	10500
Sample B + PGF-BB	14000
Sample C	0 (<5000)
30 Sample C + PGF-BB	0 (<5000)
Sample OP	8250
Sample OP + PGF-BB	5500

2) Optical microscopy: the cell growth in the wells and onto the membranes was observed under the optic microscope.

Sample A: few cells of anomalous morphology, an indication of cellular suffering, more apparent the shorter the distance from the membrane.

5 Sample B: elongated and adhered cells present at a distance from the membrane. Non-adherent spherical cells near the membrane.

Sample C: elongated and adhered cells present at a distance from the membrane. Non-adherent spherical cells near the membrane

Sample OP: elongated and adhered cells present at a distance from the  
10 membrane. Non-adherent spherical cells near the membrane

3) Electronic Microscopy: observations of membranes under the SEM

Sample A: membrane essentially without fibroblasts: however, the very unusual cellular elements present show normal morphology.

Sample B: no cell on the membrane.

15 Sample C: no cell on the membrane.

Sample OP: cells of normal morphology present on the membrane.

From data relating to the cell count (assay (1)) after trypsinization it is seen that the OP membrane reduces only slightly the cellular growth with respect to the control, while samples A and C completely abolish cellular growth(<5000, lower  
20 detection limit of the method) . Sample B made up of collagen and chondroitin-4-sulphate, also allows cellular proliferation, as shown in the cell count test.

However, it is also seen from the analyses under the optic and electron microscope that in the sample where marked inhibition of cellular growth (B) was not found, colonization of the membrane itself was absent since the fibroblasts  
25 present were all arranged around the membrane, but not on its surface.

The only membrane colonized by the fibroblasts as observed by SEM is the OP 323 membrane produced according to the process described in the previous examples. From the morphological point of view, the cells grown on the OP membrane, as observed by optical microscopy, looked healthy.

30 **Example 7: Preparation of membranes batch 40046.**

500 g of horse tendon (batch 40041) were treated exactly as described in example 3, until the attainment of collagen fibers isolated by salting (precipitation) at pH

## 5.5.

10 kg of said fibers were treated with 20 l of 1 N NaOH and left under agitation for 1 hour at room temperature then washed and brought up to pH 5.5 and at a chloride concentration of  $\leq 50$  ppm.

- 5 This treatment with 1 N NaOH besides representing compliance with an EEC directive for the purposes of the removal of potential viral contaminants and agents responsible for TSE (however much this pathology has so far never been found in horses), has led, as shown in the following examples, by the comparative and microscopic analyses, to greater purity of the collagen and presumably to a  
10 modest reduction in glycosilation. In table 4 are shown the results of the analyses performed on the membranes before (A) and after (B) NaOH treatment.

Table 4

	A	B
Hydroxyproline (d.s.)	13.14 %	13.39%
Nitrogen (d.s.)	17.86%	17.74%
Sodium (d.s.)	0.129	0.067%
Chlorides (Cl <sup>-</sup> on d.s.)	0.646	0.679%
Hexosamine (on dry s.)	0.737	0.181%

d.s.= on dry substance

- The collected and weighed fibres were dispersed in an aqueous solution of 0.3% acetic acid and at a presumed collagen concentration (as dry substance) of ~ 1%.  
15 9.48 kg of gel were obtained.

- These 9.48 kg of collagen gel were set under agitation for 1.5 hours in a Rayneri Dynavar SB 25 mixer (Groupe VMI ZI, Montaign France), at speed n.80. The gel is then transferred in a suitable homogenizer (CONDOR S.r.l. Verona) equipped with  
20 a planetary mixer and kept in a vacuum and shaken for 3 hours at speed 1 and for 3 hours at speed 2. The gel is then left in the vacuum to rest overnight.

- The gel, free from air bubbles included after this treatment, is divided into 12 x 12 cm small polystyrene trays charged with electrostatic current, in amounts of 130 g of gel/tray, corresponding to membranes with an expected weight of approx. 9  
25 mg/cm<sup>2</sup>.

The trays were put in an incubator cabinet "High Performance" Mod 2800 (F.Ili



Galli G.& P.- Milan) thermostatically set at 28°C without ventilation and therein left for approx. 120 h.

Upon exit from the exsiccator cabinet the films formed are extracted from the trays and left in contact with air for 1 hour then packed in a sterile bag. Afterwards the  
5 membranes were cut into suitable shapes, packed in a double bag and finally subjected to radiant treatment with  $\gamma$  rays at the dose of 25 Kgy.

Analysis of the membranes of batch 40046 provided the following composition:

Humidity:	15.6.%
Acetic acid content, measured by potentiometry:	2.5%
10 Content in hydroxyproline:	13.39%

Upon enzymatic digestion with collagenase the liberation kinetics of hydroxyproline, in the 40046 membranes, measured as shown in example 4 (with p-dimethylaminobenzoaldehyde), proved perfectly comparable with that of collagen membranes prepared as in example 4, i.e. without treatment with sodium  
15 hydroxide.

#### **Example 8: preparation of membranes batch 40046/LL**

Following the removal of the residual acetic acid by washing, some of membranes 40046, prepared as described in example 7, were cut into four parts and placed in distilled water, which was changed 4 consecutive times after 1 hour immersion  
20 each time.

The membranes were exsiccated by lyophilization with at a temperature ranging from -30°C to +30°C.

Membranes marked 40046/LL were obtained, which showed a wrinkled superficial appearance, basically curled and scarcely hydrophilic, characteristic of a  
25 superficially denatured proteic structure.

Analysis provided the following percentages:

Humidity: 13.5%

Acetic acid content:  $\leq 0.23\%$

Upon Differential Scanning Calorimetry (DSC) analysis, the thermal denaturation  
30 of 40046LL occurred at the temperatures  $t_{\text{start}}$  49.62°C,  $t_{\text{max}}$  56.09°C, and  $t_{\text{end}}$  62.17, against the respective values of membrane 40046 of 43.74°C, 49.52°C and 55.29°C, while the apparent heat capacity was 6.09 cal/g for membrane 40046/LL,

compared to 2.82 cal/g for the unwashed/lyophilized membrane 40046.

Membranes 40046 and 40046/LL were also subjected to the absorption and water evaporation test.

The membranes 40046 absorbed 9% of their weight of water in 4 hours, while  
5 membranes 40046/LL absorbed only 4.3%. On the other hand, the latter gave up the water absorbed with a speed 40% lower than that of water evaporation of membranes 40046.

These results indicate that the process of lyophilization is not suited for the collagen membranes as it partly degrades the proteic structure of the superficial  
10 collagen.

**Example 9. Preparation of the membranes 40036.**

The membranes 40036 were prepared as the 40046 ones (example 7) with the only exclusion of the alkaline treatment of collagen fibers with 1N NaOH.

**Example 10. Preparation of membranes P322.**

15 1% collagen gel batch n. 78631 is prepared from equine Achilles tendon, as described in example 3. 2 kg of said gel are put in a 10 litre vacuum flask for 60', for deaeration, then it was divided in 90 mm Ø plates so as to be able to have a membrane of approx. 16 mg of dry residue/cm<sup>2</sup>. The plates were air dried by spontaneous incubator exsiccation. All the operations were carried out in under  
20 controlled microbial charge. Batch 88225 of membranes marked P322 were obtained.

**Example 11: Preparation of membranes 40049A/S largely consisting of collagen type II**

Ground pig's trachea (batch RD/7) 0.9 kg in 5 l of 0.5M NaOH shaken for 5 h at  
25 room temperature then at 5°C. The fragments of fatty and/or phospholipidic material were mechanically eliminated from the supernatant.

The residue was collected on a filter consisting of a fine metallic net, washed with water 3 x 2 litres and neutralized at pH 7 with 80 ml of 1N HCl.

The mass was twice treated with 2 l of acetone each time. The hydroacetic step  
30 is eliminated, the mass is washed with water, added with 14 l of water 30 ml of 1N HCl up to pH 2.6 and 90g of pepsin from pig's gastric mucous, Merck at 700FIP U/g (batch 15506) and left under slow agitation for 24 h at 20-24°C.

5.5 l of said suspension were vacuum filtered, on buckner with octex® filters and pre-stratum of filtering aid. The filtrate, opalescent, was brought to pH 3.5 with HCl, treated with NaCl up to 0.7M and left to rest overnight.

The light precipitate, consisting of type II collagen fibers was collected by centrifugation. 80 ml of damp fibers were obtained and marked 40049A.

80 ml of fibers 40049<sup>o</sup> are put in a Spectrapor MWCO 1000 dialysis tube Ø 4.5 and length 70 cm, and therein left for 48h at room temperature with periodic changes of water.

The retented, approx. 100 ml is brought to pH 3.36 with 50% HCl solution. The gel obtained (1.18% dry residue) was divided into polystyrene petri capsules, Ø 5.5 cm, so as to give rise to 9 mg/cm<sup>2</sup> membranes, and dried first for 30 h in a stove then in air on plates at 30°C.

The resulting membranes were marked 40049A/S.

**Example 12. Analysis of collagen film under the optic microscope, scanning and transmission electron microscope**

The collagen membranes marked 40039/E or 40046, prepared as described in the examples previously described, were washed in sterile distilled H<sub>2</sub>O, for approx. 15 hours, then subjected to analysis by optic, scanning electron and transmission microscopy.

Semi-fine sections, perpendicular to the membrane surface, were stained with basic dyes of the thiazine group and observed under the optic microscope. One surface (most probably the upper one) is smooth, compact and intensely coloured; the lower surface is less homogeneous, more loose and uneven (Figure 5).

Under the *scanning electron microscope*, the membrane appeared to be formed of a three-dimensional lattice of collagen fibrillae, most of which set in longitudinal bundles parallel to the gel surface. One side of the gel, most probably the lower one, has longer fibrillae and which are arranged in a more uniform way as regards the other surface (upper), which overall is more wrinkled and dishomogeneous (Figure 6).

Under the *transmission electron microscope*, the collagen fibrillae, of varying dimensions, form a three-dimensional lattice, with predominant orientation in a parallel direction to the gel surface. The texture is, in some points, quite regular.

Most of the collagen fibrillae are linear; some are folded over and the arrangement is not always clear. As mentioned, the diameter of the fibrillae is very variable, while the periodic arrangement, when recognizable, is 640 nm as for native collagen.

5     **Example 13:           Measurement of the growth of dermal fibroblasts cultivated on collagen film**

Human dermal fibroblasts were used, isolated from skin biopsies of healthy adult subjects, cultivated in Dulbecco's Modification of Eagle's Medium (DMEM) culture medium at high glucose concentration, containing 2mM L-glutamine, 100 IU/ml  
10     penicillin, 100 mg/ml streptomycin, 1 mM Na pyruvate, non-essential amino acids (NEAA) 1X and fetal bovine serum (FBS) at a final concentration of 10%.

In this assay the fibroblasts were plated in a two well "chamber slide" (area= 8.26cm<sup>2</sup>), 30,000 cells/well in a final volume of 2 ml culture medium.

The cells were directly plated in one well, in the other before plating, was put the  
15     collagen film with the opaque side turned upwards.

The MTT test (tetrazolium salts) was used to determine the growth of cells.

This test is based on the intracellular reduction of the tetrazolium salts, by the mitochondrial dehydrogenase, in a product of brick red colour insoluble in water (formazan crystals). The crystals are solubilized with dimethyl sulphoxide and the  
20     coloured solution obtained is measured using the spectrophotometer at a wavelength of 565 nm.

The vital cells, unlike the dead ones, reduce the tetrazolium salts. This test is much used for measuring cellular vitality and as an indicator of proliferation.

The number of fibroblasts, grown on the plastic well adapted for cell-growth,  
25     approximately double by the 4<sup>th</sup> day of culture with respect to the 1<sup>st</sup> plating day.

The fibroblasts grown on the collagen film show the same tendency (Figure 7).

**Example 14. Analysis of dermal fibroblasts cultivated on collagen film under the confocal microscope**

To check the morphology of the cells cultivated on the collagen membranes and  
30     the level of growth, after 3 and 6 days of culture, the collagen membranes with the fibroblasts were fixed and stained with fluoresceinated phalloidine, that emits green radiation and highlights the cytoskeleton of actin and with rhodaminated tubulin

that emits red radiation and highlights the tubulin structures.

After staining, the membranes with the fibroblasts, were examined under the fluorescence optic microscope and the confocal microscope.

The cells cultivated on the collagen membrane were clearly visible and appeared  
5 to be distributed on different levels of the film.

After 3 days, the cells still had not reached confluence. They appeared heterogeneous: elongated with thin polygonal, triangular protrusions. In certain fields mitotic cells were observed.

At day 6, the fibroblasts, of polygonal shape and elongated, were at confluence,  
10 they covered all the membrane space (Figure 8 fibroblasts grown on collagen film at the 6<sup>th</sup> day of culture (labeling with Phalloidine) Obj: 10.0 Zoom:1.430)

**Example 15. Growth, proliferation and evaluation of the vitality of chondrocytes taken from knee cartilage of patients undergoing prosthesis surgical treatment.**

15 Collagen membranes batch 40046, prepared as described in example 7, were used in an experimental scheme suited to assess the growth, proliferation and vitality of human chondrocytes taken from knee cartilage of patients undergoing surgical treatment for prosthetic implant.

The cultures were grown in autologous serum and were examined at 0, 1, 7, 14,  
20 21 and 35 days. The growth and vitality of the cells were tested by MTT assay, 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyl tetrazolium bromide reduced into formazan by mitochondrial enzyme succinate-dehydrogenase according to Denizot F., Lang R., J Immunol Methods, 89, 271-277, 1986.

After 7 days it was surprisingly found that not only are the cells vital and healthy on  
25 the membranes in culture but that they grew more than was to be expected. Due to their impressive growth on the membranes, it was difficult for the operator to assess their proliferation degree, as they have already reached the confluence point very early.

In order to evaluate chondrocytes growth and vitality for 35 days, the protocol had  
30 to be modified: instead of plating 1.000.000 cells/cm<sup>2</sup>, they had to plate membranes 40046 with 250.000 cells/ cm<sup>2</sup>

After this modification, the same healthy morphology and the same unexpected

proliferation rate was observed after 35 days in culture.

The extremely positive results both on fibroblasts and on chondrocytes might be, at least in part, due to the additional alkaline treatment and to the additional precipitation step of the collagen fibres introduced in the preparation process.

5 **Example 16. Comparative assays to determine human chondrocytes proliferation and vitality on some collagen membranes**

$1 \times 10^4$  chondrocytes from human cartilage have been cultured for 7 days in parallel on the following membranes:

- 40046, prepared as described in example 7
  - 10 - 40046LL, prepared as described in example example 8
  - 40036, prepared as described in example example 9
  - P322, prepared as described in example 10
  - 40049/A/S, prepared as described in example 11
  - Chondro-gide, Geistlich
- 15 At the end of the established period the membranes colonized by cells have been colored with Safranin-O, che mette in evidenza i gruppi solfati caratteristici della matrice extracellulare cartilaginea sintetizzata dai condrociti vitali. Histomorphometry of the cultivated chondrocytes on the membranes has been evaluated by analysing the images and representing the results as area of
- 20 colonized part of the membrane expressed as percentage of the entire membrane. The hystogram shows that the best membranes, among those examined, are 40049/A/S and 40046. In particular, membrane 40046 has been chosen for other studies because made with equine collagen Type I already characterized from the immunological and toxicological point of view (see Bianchini P., Parma B., Arneim-
- 25 Forsh 51(I, 414-419, 2001). In figure 10 and 11 are shown the optical micropyp pictures related to chondrocytes colonization of two different membranes: Chondro-gide and membrane 40046.

## CLAIMS

- 1) Double sided collagen membranes with a porous side suitable for the adhesion and/or growth of cells and a smooth side, characterized in that the collagen is arranged at macromolecular level on the smooth side.
- 5 2) Membranes according to claim 1 wherein said collagen is chosen among: collagen of type I, II, III or IV, or a mixture consisting of at least two of the four types.
- 3) Process for the preparation of collagen membranes characterized in that a collagen gel is poured and allowed to exsiccate on a plate on which an  
10 electrostatic charge has been induced.
- 4) Process according to claim 3, wherein said collagen gel has a collagen concentration comprised between 0.5-6%
- 5) Process according to claim 3 wherein said exsiccation of the gel occurs at a temperature of less than 40°C, for a time of at least 40 hours.
- 15 6) Process according to claim 4, wherein said exsiccation temperature is between 20 and 30°C.
- 7) Process according to claim 4 wherein said exsiccation is performed in the absence of any air turbulence
- 8) Process according to claim 3, wherein said collagen gel is produced with a  
20 process that essentially comprises the following steps:
  - a) mechanical mincing of a connective tissue and homogenization into a collagen suspension,
  - b) treatment of the collagen suspension with proteolytic enzymes,
  - c) alkaline treatment of the collagen suspension to a pH value of at least 8 and  
25 neutralization with a strong acid to a pH comprised between 5 and 6,
  - d) precipitation of the collagen fibers by salting
  - e) resuspension of the precipitate in an aqueous solution diluted with a weak acid and obtainment of a collagen gel.
- 9) Process according to claim 8, wherein the following additional steps are added  
30 in between step d) and e):
  - d') resuspension of the precipitate in a strong alkaline solution with mixing for a time of at least 30',

d") precipitation of the collagen fibers by salting of the alkaline solution at pH values comprised between 5 and 6

10) Process according to claim 9, wherein said alkaline solution is 1N NaOH

11) Process according to claim 10, wherein said time is comprised between 45'  
5 and 75'

12) Process according to claims 9-10, wherein the connective tissue of step a) is derived from a mammalian.

13) Process according to claims 8-9, wherein the connective tissue of step a) is tendon.

10 14) Process according to claim 13, wherein said tendon is equine.

15) Process according to claims 8-9, wherein said connective tissue in step a) is a tracheal tissue.

16) Process according to claim 15, wherein said tracheal tissue is derived from a bovine, a suine or an equine.

15 17) Process according to claim 8-9 wherein mincing and homogenization in step a) occurs after the addition of an aqueous solution and up to the attainment of a suspension consisting of collagen particles less than 25 mesh in size.

18) Process according to claim 17 wherein the homogenization is followed by micronization.

20 19) Process according to claims 8-9 wherein the proteolytic enzyme in step b) of the process is pepsin and the treatment occurs at a pH comprised between 2 and 3 for a time comprised between 10 and 20 hours.

20) Process according to claims 8-9 wherein the resuspension of the collagen precipitate in step e) is performed at a collagen concentration comprised between  
25 0.5 and 6%.

21) Process according to claim 20 wherein said concentration is between 2 and 3%.

22) Process according to claims 8-9 wherein said diluted aqueous solution, as in step (e) of the procedure, is a solution of acetic acid.

30 23) Process according to claim 22 wherein said acetic acid solution has a concentration comprised between 0.1 and 1% (w/V).

24) Process according to claims 8-9, wherein the collagen gel obtained in step e)



of the process is further homogenized and degassed by aspiration in the vacuum.

25) Collagen membranes obtainable by the process according to claims 3-7.

26) Collagen gel obtainable by the process according to claims 8-19.

27) Collagen membranes obtained by pouring a collagen gel according to claim 26

5 and according to the process described in claims 3-7

28) Use of the collagen membranes according to claims 1, 25 and 27 as supports for the *in vitro* adhesion, growth or colonization of mammalian cells.

29) Use of the collagen membranes according to claim 28 wherein said mammalian cells are selected from: staminal cells, fibroblasts, epithelial cells,

10 endothelial cells, osteocytes and chondrocytes.

30) Membranes according to claims 1, 25 and 27 for use in therapy

31) Use of the membranes according to claim 30 for the preparation of cellular matrices for tissue reconstruction

32) Use according to claim 31 wherein said tissue reconstruction is chosen  
15 among: reconstruction of epithelial, endothelial, connective, cartilaginous, osseous and osteo-cartilaginous tissue.

33) Use of the membranes according to claim 30 for tissue reconstruction in chronic degenerative diseases.

1/10




Fig. 1




Fig. 2

2/10




FIG. 3

3/10




FIG. 4




Fig. 5




Fig. 6

6/10




Fig.7



Fig. 8



8/10




Fig. 9



Fig. 10

10/10




Fig. 11a



Fig. 11b

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 01/08872

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61L31/04 C08L89/06

According to International Patent Classification (IPC) or to both national classification and IPC

## **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61L A61K C08L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

## **C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 18638 A (GEISTLICH SOEHNE AG; GEISTLICH P (CH); ECKMAYER Z (DE); BOYLE P (US)) 13 July 1995 (1995-07-13) cited in the application page 2, paragraph 3 -page 3, paragraph 2	1,2,25, 27-33
A	WO 00 29484 A (BIOCOMPOSITES LLC) 25 May 2000 (2000-05-25) page 27, line 11 - line 13	1-3,25
A	WO 98 44809 A (CLEARCOLL PTY LTD; VIDAL LINUS (AU); VIDAL BENEDICTO DE CAMPOS (BR)) 15 October 1998 (1998-10-15) cited in the application page 5, line 14 -page 7, line 9 --- -/-	3-24,26

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

6 December 2001

Date of mailing of the international search report

19/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Heck, G

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 01/08872

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 5 785 983 A (BONFANTI GIOVANNI ET AL)  28 July 1998 (1998-07-28)  cited in the application  example 1  claims 1,2</p>	<p>1,2,25,  27</p>

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 33 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

---

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No

PCT/EP 01/08872

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9518638	A	13-07-1995	CA 2180659 A1	13-07-1995
			EP 0738161 A1	23-10-1996
			WO 9518638 A1	13-07-1995
			JP 9507144 T	22-07-1997
			US 5837278 A	17-11-1998
WO 0029484	A	25-05-2000	AU 1627800 A	05-06-2000
			WO 0029484 A1	25-05-2000
WO 9844809	A	15-10-1998	AU 729068 B2	25-01-2001
			AU 6713198 A	30-10-1998
			WO 9844809 A1	15-10-1998
			EP 0969740 A1	12-01-2000
			JP 2001519695 T	23-10-2001
US 5785983	A	28-07-1998	IT 1249315 B	22-02-1995
			AT 132517 T	15-01-1996
			CA 2064993 A1	24-11-1992
			CN 1066790 A	09-12-1992
			DE 69207263 D1	15-02-1996
			DE 69207263 T2	15-05-1996
			EP 0514691 A2	25-11-1992
			JP 5117162 A	14-05-1993
			KR 229304 B1	01-11-1999